Walgreens has sold more shares of drug distributor Cencora for proceeds of about $300 million in the latest effort to pay ...

The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

Cencora has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale ...

in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage ...

Raises FY25 revenue view to 8%-10% from 7%-9%. Consensus is for FY25 EPS $15.20 and for revenue $319.54B.Cencora (COR) updated its FY25 guidance to better reflect the ...

Walgreens and Cencora have been working together since 2013, when the drug distributor was still known as AmerisourceBergen. But recently Walgreens has been winnowing its stake in Cencora as the ...